Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Development of research on nursing diagnoses in Brazilian graduate programs.

Hirano GSB, Lopes CT, Barros ALBL.

Rev Bras Enferm. 2019 Aug 19;72(4):926-932. doi: 10.1590/0034-7167-2018-0259. English, Portuguese.

2.

NUT carcinoma of the nasal cavity that responded to a chemotherapy regimen for Ewing's sarcoma family of tumors: a case report.

Arimizu K, Hirano G, Makiyama C, Matsuo M, Sasaguri T, Makiyama A.

BMC Cancer. 2018 Nov 19;18(1):1134. doi: 10.1186/s12885-018-5087-x.

3.

A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy.

Kumagai H, Kusaba H, Yamanaka T, Nio K, Inadomi K, Takayoshi K, Ito M, Tamura S, Makiyama A, Makiyama C, Hirano G, Shibata Y, Shirakawa T, Mitsugi K, Ariyama H, Esaki T, Akashi K, Baba E.

Medicine (Baltimore). 2018 Jun;97(25):e11042. doi: 10.1097/MD.0000000000011042.

4.

Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer.

Ito M, Kusaba H, Mukaide S, Kishimoto J, Shimokawa H, Tamura S, Makiyama A, Hirano G, Oda H, Shirakawa T, Komoda M, Uchino K, Tanaka R, Mitsugi K, Esaki T, Arita S, Ariyama H, Akashi K, Baba E.

Anticancer Drugs. 2017 Nov;28(10):1166-1173. doi: 10.1097/CAD.0000000000000562.

PMID:
28906258
5.

Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer.

Makiyama A, Arimizu K, Hirano G, Makiyama C, Matsushita Y, Shirakawa T, Ohmura H, Komoda M, Uchino K, Inadomi K, Arita S, Ariyama H, Kusaba H, Shinohara Y, Kuwayama M, Kajitani T, Oda H, Esaki T, Akashi K, Baba E.

Gastric Cancer. 2018 May;21(3):464-472. doi: 10.1007/s10120-017-0759-9. Epub 2017 Aug 10.

PMID:
28799048
6.

Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer.

Inadomi K, Kusaba H, Matsushita Y, Tanaka R, Mitsugi K, Arimizu K, Hirano G, Makiyama A, Ohmura H, Uchino K, Hanamura F, Shibata Y, Kuwayama M, Esaki T, Takayoshi K, Arita S, Ariyama H, Akashi K, Baba E.

Anticancer Res. 2017 May;37(5):2663-2671.

PMID:
28476842
7.

Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.

Arita S, Shirakawa T, Matsushita Y, Shimokawa HK, Hirano G, Makiyama A, Shibata Y, Tamura S, Esaki T, Mitsugi K, Ariyama H, Kusaba H, Akashi K, Baba E.

Anticancer Res. 2016 Apr;36(4):1959-66.

PMID:
27069187
8.

Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.

Nio K, Arita S, Isobe T, Kusaba H, Kohashi K, Kajitani T, Tamura S, Hirano G, Mitsugi K, Makiyama A, Esaki T, Ariyama H, Oda Y, Akashi K, Baba E.

Cancer Chemother Pharmacol. 2015 Apr;75(4):829-35. doi: 10.1007/s00280-015-2706-y. Epub 2015 Feb 22.

PMID:
25702050
9.

Why is radiofrequency ablation therapy applied for hepatocellular carcinoma up to 3 nodules and smaller than 3 cm in tumor size?

Hirano G, Iwata K, Anan A, Sohda T, Kunimoto H, Yotsumoto K, Fukunaga A, Sakurai K, Tanaka T, Iwashita H, Yokoyama K, Morihara D, Takeyama Y, Irie M, Shakado S, Sakisaka S.

Hepatogastroenterology. 2014 Nov-Dec;61(136):2305-10.

PMID:
25699371
10.

Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging as a useful detection method for advanced primary biliary cirrhosis.

Takeyama Y, Tsuchiya N, Kunimoto H, Fukunaga A, Sakurai K, Hirano G, Yokoyama K, Morihara D, Anan A, Irie M, Shakado S, Sohda T, Sakisaka S.

Hepatol Res. 2015 Oct;45(10):E108-14. doi: 10.1111/hepr.12470. Epub 2015 Mar 2.

PMID:
25560223
11.

Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.

Hirano G, Makiyama A, Makiyama C, Esaki T, Oda H, Uchino K, Komoda M, Tanaka R, Matsushita Y, Mitsugi K, Shibata Y, Kumagai H, Arita S, Ariyama H, Kusaba H, Akashi K, Baba E.

Anticancer Res. 2015 Jan;35(1):371-7.

PMID:
25550574
12.

Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.

Morihara D, Watanabe H, Takata K, Iwashita H, Tsuchiya N, Kunimoto H, Kuno S, Fukunaga A, Yotsumoto K, Tanaka T, Sakurai K, Hirano G, Yokoyama K, Nishizawa S, Yoshikane M, Anan A, Takeyama Y, Kitamura Y, Iwata K, Irie M, Shakado S, Sohda T, Sakisaka S.

Eur J Gastroenterol Hepatol. 2015 Jan;27(1):55-64. doi: 10.1097/MEG.0000000000000208.

PMID:
25370853
13.

Immunohistochemical demonstration of transferrin receptor 1 and 2 in human hepatocellular carcinoma tissue.

Sakurai K, Sohda T, Ueda S, Tanaka T, Hirano G, Yokoyama K, Morihara D, Aanan A, Takeyama Y, Irie M, Iwata K, Syakado S, Noritomiz T, Yamashita Y, Sakisaka S.

Hepatogastroenterology. 2014 Mar-Apr;61(130):426-30.

PMID:
24901155
14.

Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma.

Shakado S, Iwata K, Tsuchiya N, Kunimoto H, Yotsumoto K, Fukunaga A, Kuno S, Tanaka T, Sakurai K, Iwashita H, Hirano G, Yokoyama K, Morihara D, Nishizawa S, Takeyama Y, Irie M, Sohda T, Kora S, Yoshimitsu K, Sakisaka S.

Hepatogastroenterology. 2014 May;61(131):557-62.

PMID:
26176035
15.

Desmoplastic small round cell tumors in a young man.

Hirano G, Irie M, Nakashima Y, Shakado S, Sohda T, Tanaka T, Takamatsu Y, Aoki M, Tamura K, Nabeshima K, Sakisaka S.

Intern Med. 2013;52(17):1909-14.

16.

3-Hydroxyl-3-methylglutaryl-coenzyme A reductase is up regulated in hepatocellular carcinoma associated with paraneoplastic hypercholesterolemia.

Sohda T, Iwata K, Hirano G, Sakurai K, Yokoyama K, Morihara D, Takeyama Y, Irie M, Shakado S, Sakisaka S.

Med Mol Morphol. 2013 Dec;46(4):239-42. doi: 10.1007/s00795-013-0042-z. Epub 2013 Apr 3.

PMID:
23549978
17.

Levels of the oxidative stress marker γ-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease.

Irie M, Sohda T, Iwata K, Kunimoto H, Fukunaga A, Kuno S, Yotsumoto K, Sakurai K, Iwashita H, Hirano G, Ueda SI, Yokoyama K, Morihara D, Nishizawa S, Anan A, Takeyama Y, Sakamoto M, Shakado S, Sakisaka S.

J Int Med Res. 2012;40(3):924-33.

PMID:
22906265
18.

Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells.

Uchino K, Hirano G, Hirahashi M, Isobe T, Shirakawa T, Kusaba H, Baba E, Tsuneyoshi M, Akashi K.

Exp Cell Res. 2012 Sep 10;318(15):1799-807. doi: 10.1016/j.yexcr.2012.04.011. Epub 2012 Jun 5.

PMID:
22677041
19.

Eosinophilic gastroenteritis in a patient with chronic hepatitis C who received treatment with pegylated interferon.

Hirano G, Fukunaga A, Sohda T, Kunimoto H, Yotsumoto K, Sakurai K, Iwashita H, Ueda S, Yokoyama K, Morihara D, Tomioka Y, Anan A, Yamaguchi M, Takeyama Y, Eguchi K, Sakamoto M, Irie M, Iwata K, Shakado S, Aoyagi K, Sakisaka S.

Clin J Gastroenterol. 2012 Apr;5(2):127-30. doi: 10.1007/s12328-012-0289-2. Epub 2012 Feb 24.

PMID:
26182155
20.

Limitation of repeated radiofrequency ablation in hepatocellular carcinoma: proposal of a three (times) × 3 (years) index.

Yokoyama K, Anan A, Iwata K, Nishizawa S, Morihara D, Ueda S, Sakurai K, Iwashita H, Hirano G, Sakamoto M, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S.

J Gastroenterol Hepatol. 2012 Jun;27(6):1044-50. doi: 10.1111/j.1440-1746.2012.07134.x.

PMID:
22433056
21.

Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma.

Hirano G, Sakurai K, Sohda T, Kunimoto H, Yotsumoto K, Fukunaga A, Iwashita H, Ueda S, Yokoyama K, Morihara D, Takeyama Y, Sakamoto M, Irie M, Iwata K, Shakado S, Sakisaka S.

Hepatogastroenterology. 2012 Oct;59(119):2264-8.

PMID:
22389294
22.

Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma.

Morihara D, Iwata K, Hanano T, Kunimoto H, Kuno S, Fukunaga A, Yotsumoto K, Takata K, Tanaka T, Sakurai K, Iwashita H, Ueda S, Hirano G, Yokoyama K, Nakane H, Nishizawa S, Yoshikane M, Anan A, Takeyama Y, Kakumitsu S, Kitamura Y, Sakamoto M, Irie M, Shakado S, Sohda T, Watanabe H, Sakisaka S.

Hepatol Res. 2012 Jul;42(7):658-67. doi: 10.1111/j.1872-034X.2012.00969.x. Epub 2012 Mar 2.

PMID:
22380706
23.

A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin.

Shakado S, Akehi Y, Yotsumoto K, Fukunaga A, Kuno S, Tanaka T, Sakurai K, Iwashita H, Ueda S, Hirano G, Yokoyama K, Morihara D, Nishizawa S, Sakamoto M, Anan A, Takeyama Y, Irie M, Iwata K, Sohda T, Sakisaka S.

Clin J Gastroenterol. 2011 Aug;4(4):255-261. doi: 10.1007/s12328-011-0228-7. Epub 2011 Jun 10.

PMID:
26189530
24.

Involvement of riboflavin kinase expression in cellular sensitivity against cisplatin.

Hirano G, Izumi H, Yasuniwa Y, Shimajiri S, Ke-Yong W, Sasagiri Y, Kusaba H, Matsumoto K, Hasegawa T, Akimoto M, Akashi K, Kohno K.

Int J Oncol. 2011 Apr;38(4):893-902. doi: 10.3892/ijo.2011.938. Epub 2011 Feb 9.

PMID:
21308351
25.

Circadian disruption accelerates tumor growth and angio/stromagenesis through a Wnt signaling pathway.

Yasuniwa Y, Izumi H, Wang KY, Shimajiri S, Sasaguri Y, Kawai K, Kasai H, Shimada T, Miyake K, Kashiwagi E, Hirano G, Kidani A, Akiyama M, Han B, Wu Y, Ieiri I, Higuchi S, Kohno K.

PLoS One. 2010 Dec 23;5(12):e15330. doi: 10.1371/journal.pone.0015330.

26.

Clinical features of Wilson disease: Analysis of 10 cases.

Takeyama Y, Yokoyama K, Takata K, Tanaka T, Sakurai K, Matsumoto T, Iwashita H, Ueda S, Hirano G, Hanano T, Nakane H, Morihara D, Nishizawa S, Yoshikane M, Anan A, Kakumitsu S, Kitamura Y, Sakamoto M, Irie M, Iwata K, Shakado S, Sohda T, Watanabe H, Hirose S, Hayashi H, Noritomi T, Yamashita Y, Sakisaka S.

Hepatol Res. 2010 Dec;40(12):1204-11. doi: 10.1111/j.1872-034X.2010.00728.x. Epub 2010 Oct 7.

PMID:
21040274
27.

Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells.

Hirano G, Izumi H, Kidani A, Yasuniwa Y, Han B, Kusaba H, Akashi K, Kuwano M, Kohno K.

Mol Cancer Res. 2010 Jun;8(6):864-72. doi: 10.1158/1541-7786.MCR-09-0458. Epub 2010 Jun 8.

28.

Y-box binding protein-1 is a novel molecular target for tumor vessels.

Takahashi M, Shimajiri S, Izumi H, Hirano G, Kashiwagi E, Yasuniwa Y, Wu Y, Han B, Akiyama M, Nishizawa S, Sasaguri Y, Kohno K.

Cancer Sci. 2010 Jun;101(6):1367-73. doi: 10.1111/j.1349-7006.2010.01534.x. Epub 2010 Feb 16.

29.

Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth.

Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D, Fukunaka Y, Yasuniwa Y, Naito S, Nishizawa S, Sasaguri Y, Kohno K.

Cancer Res. 2009 Apr 1;69(7):3148-56. doi: 10.1158/0008-5472.CAN-08-2334. Epub 2009 Mar 24.

30.

Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.

Makiyama A, Qin B, Uchino K, Shibata Y, Arita S, Isobe T, Hirano G, Kusaba H, Baba E, Akashi K, Nakano S.

Anticancer Drugs. 2009 Feb;20(2):123-30. doi: 10.1097/CAD.0b013e3283218080.

PMID:
19209029
31.

Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high-mobility group protein B1.

Shiota M, Izumi H, Miyamoto N, Onitsuka T, Kashiwagi E, Kidani A, Hirano G, Takahashi M, Ono M, Kuwano M, Naito S, Sasaguri Y, Kohno K.

Cancer Sci. 2008 Oct;99(10):1950-9. doi: 10.1111/j.1349-7006.2008.00912.x.

32.

Twist and p53 reciprocally regulate target genes via direct interaction.

Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Takahashi M, Naito S, Kohno K.

Oncogene. 2008 Sep 18;27(42):5543-53. doi: 10.1038/onc.2008.176. Epub 2008 May 26.

PMID:
18504427
33.

Myeloid/natural killer cell blast crisis representing an additional translocation, t(3;7)(q26;q21) in Philadelphia-positive chronic myelogenous leukemia.

Henzan H, Yoshimoto G, Okeda A, Nagasaki Y, Hirano G, Takase K, Tanimoto T, Miyamoto T, Fukuda T, Nagafuji K, Harada M.

Ann Hematol. 2004 Dec;83(12):784-8. Epub 2004 Aug 18.

PMID:
15322764
34.

Analgesic effects of thoracic epidural bupivacaine and fentanyl.

Hudes ET, Hirano GM, Kashin BA, Ho K, MacDonald IA, Shine K.

Can J Anaesth. 1994 Nov;41(11):1123. No abstract available.

PMID:
7828263
35.

A comparison of morphine-perphenazine and midazolam on preoperative sedation and arterial oxygen saturation.

Hudes ET, Marans HJ, Shine K, Scott AC, Hirano GM.

Can J Anaesth. 1991 Mar;38(2):187-90.

PMID:
2021987
36.

Intraoperative prochlorperazine for prevention of post-operative nausea and vomiting.

Cramb R, Fargas-Babjak A, Hirano G.

Can J Anaesth. 1989 Sep;36(5):565-7.

PMID:
2791180
37.

Recovery room oxygenation: a comparison of nasal catheters and 40 per cent oxygen masks.

Hudes ET, Marans HJ, Hirano GM, Scott AC, Ho K.

Can J Anaesth. 1989 Jan;36(1):20-4.

PMID:
2644049
38.

[Studies on the neurophysiological properties of cerebellar direct cortical responses in rabbit].

Hirano G.

Seishin Shinkeigaku Zasshi. 1966 Jan;68(1):93-101. Japanese. No abstract available.

PMID:
5948550

Supplemental Content

Loading ...
Support Center